JanOne is a biotechnology company dedicated to developing treatments for diseases that cause severe pain and reducing the reliance on opioid prescriptions. Their focus is on treating conditions such as Peripheral Artery Disease (PAD), aiming to bring non-addictive solutions to the market and alleviate the pain experienced by millions of Americans.
With promising Phase 2a clinical trial results for their treatment JAN101, JanOne is advancing towards Phase 2b trials expected to begin in late 2020. By addressing the source of pain and offering potential advancements in non-addictive pain relief, JanOne aims to make a significant impact in reducing opioid addiction and improving the lives of those suffering from debilitating pain.
Generated from the website